Researchers are exploring the use of biomimetic dendritic cell-based nanovaccines to reprogram the immune microenvironment and enhance tumor immunotherapy. These nanovaccines are being investigated for their potential to treat various types of cancer, including breast, colorectal, and fibrosarcoma. The approach involves using dendritic cells and other strategies, such as combining neoantigens with in situ cancer vaccination, to induce personalized immunity and reshape the tumor microenvironment.